Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
As of September 30, 2018 we had Note Receivable due from Related Party of $4,551 and as of September 30, 2019 we had Note Receivable Due from Related Party of 0.
The Decrease in Note Receivable from Related Party is attributable to satisfaction of a $4,551 Note payable to the Company for cash consideration of $4,551.
As of September 30, 2019 we had Accounts Receivable, Related Party of $43,460 and as of September 30, 2018 we had Accounts Receivable, Related Party of $0.
The increase in Accounts Receivable, Related Party is attributable to:
(a) The derecognition of $29,186 of unearned income during the quarter ended December 31, 2018 such unearned income recognized prior to September 30, 2018 due to adoption the by the Company of FASB ASU 2014-09 beginning in the fiscal year ended September 30, 2019.
(b) The recognition by the Company during the quarter ended December 31, 2018 of an aggregate of $27,424 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
(c) The recognition by the Company during the quarter ended March 31, 2019 of an aggregate of $27,425 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
(d) The recognition by the Company during the quarter ended June 30, 2019 of an aggregate of $27,425 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
(e) The recognition by the Company during the quarter ended September 30, 2019 of an aggregate of $27,726 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
As of September 30, 2018 we had Prepaid Expenses of $8,259 and as of September 30, 2019 we had Prepaid Expenses of $76.
The decrease in Prepaid Expenses of approximately 99% is attributable to:
recognition by the Company of $7,259 of Research and Development expenses which had been paid for in a prior period
derecognition by the Company of $1,000 compensation prepaid to a former employee deemed uncollectible by the Company during the quarter ended December 31, 2018
offset by
The recognition by the Company of $76 of prepaid expenses attributable to the issuance to Dr. Harry Lander by KCL Therapeutics, Inc. (“KCL”) of 5,000,000 shares of KCL’s common stock as prepayment for services to be performed in subsequent periods.
As of September 30, 2019 we had Accrued Interest Receivable of $0 and as of September 30, 2018 we had Accrued Interest Receivable of $7,672.
The decrease in Accrued Interest Receivable is primarily attributable to
(a)accrued interest due to the Company but unpaid settled by the receipt by the Company of 250,000 of the Preferred Series M shares of Zander Therapeutics, Inc. in satisfaction of interest receivable accrued but unpaid due to the Company by Entest Group, Inc.
(b) The cancellation pursuant to its terms and conditions of a $63,000 Note Receivable and all accrued interest thereon issued to the Company in consideration of a Convertible Note Payable
(c) a reserve of 100% having been established with regards to interest accrued but not yet paid on Notes Receivable issued to the Company in consideration of Convertible Notes Payable issued by the Company ( “Collateral Notes Receivable”). The Collateral Notes Receivable contain provisions allowing the Borrower to cancel payment obligation in the event that the Company becomes noncurrent with regard to the Company’s reporting obligation under the Securities and Exchange Act of 1934. The Company became noncurrent with regard to the Company’s reporting obligation under the Securities and Exchange Act of 1934.as of the due date of the Company’s quarterly report for the Company’s quarter ended march 31, 2019.
As of September 30, 2018 we had Prepaid Rent of $14,270 and as of September 30, 2019 we had Prepaid Rent of $0.
The decrease in Prepaid Rent is attributable to:
The recognition of rental expense with regards to $5,000 prepaid by the Company
The acceptance by the Company of 475,000 of the Preferred Series M shares of Zander Therapeutics, Inc. in satisfaction of rent prepaid by the Company to Entest Biomedical, Inc.
As of September 30, 2018 we had Investment Securities of $166,247 and as of September 30, 2019 we had Investment Securities of $19,969.
The decrease in Investment Securities of approximately 88% is attributable to:
(a) The sale by the Company of 8,000,000 common shares of Entest Group, Inc. and 185,852 of the nonvoting convertible preferred shares of Entest Group, Inc. for aggregate consideration of $49,858.
(b)The acceptance by the Company of 725,000 of the Preferred Series M shares of Zander Therapeutics, Inc. in satisfaction of interest receivable accrued but unpaid due to the Company by Entest Group, Inc. and rent prepaid to Entest Biomedical Inc.
(c) The revaluation as of September 30, 2019 of 725,000 of the Preferred Series M shares of Zander Therapeutics, Inc. owned by the Company as of June 30, 2019
(d) The revaluation as of September 30, 2019 of 470,588 of the common shares of Zander Therapeutics, Inc. owned by the Company as of June 30, 2019.
As of September 30, 2019 we had Accrued Interest Payable of $525,335 and as of September 30, 2018 we had Accrued Interest Payable of $292,094.
The increase in Accrued Interest Payable of approximately 79% is attributable to additional interest accrued but unpaid on Notes and Convertible Notes issued by the Company during the twelve months ended September 30, 2019 offset by:
(a)The payment of $8,520 of interest accrued but unpaid during the quarter ended December 31, 2018
(b) The satisfaction of $9,555 of interest accrued but unpaid during the quarter ended December 31, 2018 by the issuance of common stock.
(c) The payment of $3,000 of interest accrued but unpaid during the quarter ended March 31, 2019
(d) The satisfaction of $19,343 of interest accrued but unpaid during the quarter ended March 31, 2019 by the issuance of common stock
(e) The satisfaction of $9,344 of interest accrued but unpaid during the quarter ended June 30, 2019 by the issuance of common stock.
(f) the derecognition of $2,499 of interest accrued but unpaid on a Convertible Note issued by the Company in the face amount of $63,000 which was cancelled during the quarter ended June 30, 2019 pursuant to its terms and conditions.
(g) The satisfaction of $4,370 of interest accrued but unpaid during the quarter ended September 30, 2019 by the issuance of common stock
(h) The payment of $1,828 of interest accrued but unpaid during the quarter ended September 30, 2019.
(i) the derecognition of $3,288 of interest accrued but unpaid on a Convertible Note issued by the Company in the face amount of $50,000 which was cancelled during the quarter ended September 30, 2019 pursuant to its terms and conditions
As of September 30, 2018, we had Accrued Payroll of $655,663 and as of September 30, 2019 we had Accrued Payroll of $972,158.
The increase in accrued payroll of approximately 48% is attributable to:
$126,000 in salary expense due to the Company’s Chief Executive Officer incurred but unpaid during the twelve months ended September 30, 2019.
$162,000 in salary expense due to the Company’s former Chief Financial Officer incurred but unpaid during the twelve months ended September 30, 2019.
$28,495 in salary expense due to the Company’s former President and Chief Scientific Officer incurred but unpaid during the nine months ended June 30, 2019.
As of September 30, 2018 we had a Derivative Liability of $6,736,607 and as of September 30, 2019 we had a Derivative Liability of $7,200,528.
The increase in Derivative Liability of 7% is attributable to the recognition by the Company of embedded derivatives on Convertible Notes Payable with an aggregate face value of $2,215,421 outstanding as of September 30, 2019.
As of September 30, 2019 we had unearned income of $0 and as of September 30, 2018 we had Unearned Income of $68,000.
The decrease in Unearned Income is attributable to:
(a) The derecognition of $29,186 of unearned income recognized prior to September 30, 2018 due to adoption the by the Company of FASB ASU 2014-09 beginning in the fiscal year ended September 30, 2019 and
(b) The recognition by the Company during the six months ended March 31, 2019 of an aggregate of $38,814 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
With regards to the aforementioned license, On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.
As of September 30, 2019 we had Convertible Notes Payable, Net of Unamortized Discount, of $1,431,845 and as of September 30, 2019 we had Convertible Notes Payable, Net of Unamortized Discount, of $2,058,571.
The increase in Convertible Notes Payable, Net of Unamortized Discount, of approximately 30.4 % is primarily attributable to:
Issuance of an aggregate principal amount of $351,000 of Convertible Notes Payable and recognition of penalty principal of $3,000 during the nine months ended June 30, 2019. The issuance of these Notes amounted in the recognition of an aggregate of discounts attributable to beneficial conversion features of $351,000 which are amortized under the Interest Method over the respective duration of the Notes.
Issuance of an aggregate principal amount of $135,151 of Convertible Notes Payable during the three months ended September 30, 2019. The issuance of these Notes amounted in the recognition of an aggregate of discounts attributable to beneficial conversion features of $135,151 which are amortized under the Interest Method over the respective duration of the Notes.
Amortization of $1,407,089 of Discounts on Convertible Notes
Offset by:
cancellation of a $63,000 Convertible Note pursuant to its terms and conditions
cancellation of a $50,000 Convertible Note pursuant to its terms and conditions
satisfaction in cash of $20,000 of principal convertible indebtedness during the quarter ended September 30, 2019
conversion of $708,850 of principal amounts outstanding on Convertible Notes into equity securities of the Company during the year ended September 30, 2019.
During the year ended September 30, 2018 we had Notes Payable of $227 and during the year ended September 30, 2019 we had Notes Payable of $88,627.
The increase in Notes Payable of approximately 38,942% is attributable to borrowings incurred by the Company during the twelve months ended September 30, 2019 the proceeds of which were utilized for general corporate purposes.
During the year ended September 30, 2019 we had Accounts Payable of $92,000 and during the year ended September 30, 2018 we had Accounts Payable of $80,567 representing an increase of 14% primarily attributable to obligations incurred by the Company in the ordinary course of business.
Material Changes in Results of Operations
Revenues from continuing operations were $110,000 for the twelve months ended September 30, 2019 and $100,000 for the same period ended 2018. $110,000 of revenue recognized during the year ended September 30, 2019 consisted of $100,000 related to an anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and $10,000 of minimum royalties recognized during the twelve months ended September 30 2019 pursuant to the same license.
With regards to the aforementioned license, On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.
Operating Loss for the twelve months ended September 30, 2019 was $756,785 as opposed to Operating Loss recognized in the same period ended 2018 of $1,425,783. The decrease in Operating Loss recognized in the twelve months ended 2019 as opposed to the twelve months ended 2018 is attributable to higher General and Administrative, Consulting, and Research and Development expenses recognized during the twelve months ended September 30, 2018 as compared to the same period ended 2019.
Net Los for the year ended September 30, 2019 was $2,623,176 which was approximately 44% less than Net Loss for the same period ended 2018 which was $4,715,200. The decrease in Net Loss is primarily attributable to a larger Derivative Expense recognized during the year ended September 30 2019 when compared to the same period ended 2018.
As of September 30, 2019 we had $7,855 in cash on hand and current liabilities of $11,002,904 such liabilities consisting of Accounts Payable, Notes Payable, Convertible Notes Payable ( Net of Unamortized Discount), Derivative Liability Recognized, Accrued Rent and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.
As of September 30, 2019 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.